<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783406</url>
  </required_header>
  <id_info>
    <org_study_id>A7881010</org_study_id>
    <nct_id>NCT00783406</nct_id>
  </id_info>
  <brief_title>Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.</brief_title>
  <acronym>A7881010</acronym>
  <official_title>A Phase 2A, Double Blind (3rd Party Open), 4 Way Cross-Over, Placebo Controlled Study To Investigate The Pharmacokinetics, Safety, Toleration And Efficacy Of Single Inhaled Doses Of PF-00610355 In Moderate COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355
      in the chronic obstructive pulmonary disease (COPD) population. The doses in this study are
      intended to explore the anticipated clinical dose range.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients.</measure>
    <time_frame>up to 8 days post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety &amp; toleration of single inhaled doses of PF-00610355 in COPD patients</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the efficacy of a single inhaled dose of PF-00610355 in COPD patients.</measure>
    <time_frame>up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the exposure/response relationship of PF-00610355.</measure>
    <time_frame>up to 8 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>PF- 00610355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00610355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF -00610355</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>dry powder inhaler, 1472 mcg, single dose</description>
    <arm_group_label>PF- 00610355</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>dry powder inhaler, 736 mcg, single dose</description>
    <arm_group_label>PF-00610355</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>dry powder inhaler, 368 mcg, single dose</description>
    <arm_group_label>PF -00610355</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-bronchodilator FEV1/ FVC ratio of &lt;0.7.

          -  Post bronchodilator FEV1 of 50-80% (inclusive) of predicted.

          -  Body Mass Index (BMI) of less than 35 kg/m2; and a total body weight greater that 40
             kg.

          -  Current smokers, or ex-smokers who have abstained from smoking for at least 6 months.

        Exclusion Criteria:

          -  Subjects having more than 2 exacerbations requiring treatment with oral steroids or
             hospitalization for the treatment of COPD in the previous year.

          -  History of lower respiratory tract infection or significant disease instability during
             the month preceding screening or during the period between screening and
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7881010&amp;StudyName=Safety%2C%20Toleration%20and%20Efficacy%20of%20Single%20Inhaled%20Doses%20of%20PF-00610355%20in%20Chronic%20Obstructive%20Pulmonary%20%28COPD%29%20Patients.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <disposition_first_submitted>March 24, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 1, 2010</disposition_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

